Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p353-353, 185p
- Subject
- Language
- ISSN
- 0732183X